Bincy Augustine
Daiichi Sankyo
4 Papers
Bincy Augustine is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Medicine & Trastuzumab. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
Matthew D. Galsky,Gianluca Del Conte,Silvia Foti,Evan Y. Yu,Jean-Pascal Machiels,Bernard Doger,Andrea Necchi,Filippo de Braud,Erika Hamilton,Audrey Hennequin,Tom Van den Mooter,Philip R. Debruyne,Irene Moreno,Hendrik-Tobias Arkenau,Zenta Tsuchihashi,Fu-Chih Cheng,Bincy Augustine,Benjamin Cheng,Daniel Barrios,Diana Lüftner +19 more
TL;DR: In this article , a phase 1b, 2-part, open-label, multicenter study of T-DXd in combination with nivo in pts with HER2-expressing advanced/metastatic UC (NCT03523572).
71
Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
Erika Hamilton,Charles L. Shapiro,Daniel P. Petrylak,Valentina Boni,Miguel Martín,Gianluca Del Conte,Javier Cortes,Laila Agarwal,Hendrik-Tobias Arkenau,Antoinette R. Tan,Philip R. Debruyne,Anna Minchom,Annemie Rutten,Frances Valdes-Albini,Evan Y. Yu,Bincy Augustine,Anthony Michael D'amelio,Daniel Barrios,Sara A. Hurvitz +18 more
TL;DR: T-DXd as mentioned in this paper is a novel antibody-drug conjugate composed of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and membrane-permeable topoisomerase I inhibitor payload.
46
162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
Erika Hamilton,Charles L. Shapiro,Valentina Boni,M. Martin Jimenez,Gianluca Del Conte,Jorge E. Cortes,Laila Saied Agrawal,Hendrik-Tobias Arkenau,A. Tan,Philip R. Debruyne,Anna Minchom,Annemie Rutten,Frances Valdes-Albini,Eric Chi-Wang Yu,F. Suto,Fu-Chih Cheng,Bincy Augustine,Benjamin Cheng,Daniel Barrios,Sara A. Hurvitz +19 more
TL;DR: In this article , T-DXd showed efficacy and safety in pts with HER2+ metastatic breast cancer (MBC) with prior T-DM1, and nivo 360 mg IV Q3W.
30
Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
Hossein Borghaei,Benjamin Besse,Aditya Bardia,Julien Mazieres,Sanjay Popat,Bincy Augustine,Anthony Michael D'amelio,Daniel Barrios,Hope S. Rugo +8 more
TL;DR: T-DXd is an antibody-drug conjugate composed of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and potent topoisomerase I inhibitor that has shown promise in a phase II trial in patients with central giant cell granuloma.
23